A Study To Evaluate D1 Receptor Occupancy (RO) Following Single Dose of PF-06412562 In Healthy Male Volunteers
NCT ID: NCT02124213
Last Updated: 2014-12-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
5 participants
INTERVENTIONAL
2014-09-30
2014-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
CROSSOVER
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohor 1 - 30 mg
Cohort will include approximately 4 HVs/completers who will receive a single 30 mg dose of PF-06412562.
30 mg PF-06412562
Subject will receive a single dose of 30 mg PF-06412562
Cohort 2 ( adaptive dose, optional)
Cohort 2 will include approximately 4 HVs/completers who will receive a single dose of PF-06412562. The dose will be selected based on the results obtained for Cohort 1.
PF-06412562
The dose will be selected based on the results obtained for Cohort 1. This Cohort is optional.
Cohort 3 ( adaptive dose, optional)
Cohort 2 will include approximately 4 HVs/completers who will receive a single dose of PF-06412562. The dose will be selected based on the results obtained for Cohort 1 and Cohort 2.
PF-06412562
The dose will be selected based on the results obtained for Cohort 1 and Cohort 2.
This Cohort is optional.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
30 mg PF-06412562
Subject will receive a single dose of 30 mg PF-06412562
PF-06412562
The dose will be selected based on the results obtained for Cohort 1. This Cohort is optional.
PF-06412562
The dose will be selected based on the results obtained for Cohort 1 and Cohort 2.
This Cohort is optional.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
20 Years
55 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Karolinska Trial Alliance (KTA) M62
Huddinge, Stockholm County, Sweden
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2013-004356-37
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
B7441005
Identifier Type: -
Identifier Source: org_study_id